Advertisement

ADVERTISEMENT

non-small cell lung cancer

Review
NGS Testing in Non–Small Cell Lung Cancer
09/19/2023
Winston Wong, PharmD
Gordon Kuntz
Winston Wong, PharmD, and Gordon Kuntz provide an update on the current status of the research and barriers for using next-generation sequencing in NSCLC and summarize the discussion and next steps that the NGS Institute’s NSCLC Subcommittee...
Winston Wong, PharmD, and Gordon Kuntz provide an update on the current status of the research and barriers for using next-generation sequencing in NSCLC and summarize the discussion and next steps that the NGS Institute’s NSCLC Subcommittee...
Winston Wong, PharmD, and Gordon...
09/19/2023
Journal of Clinical Pathways
Thomas Stricker, MD.
Videos
Clinical Value of Timely Targeted Therapy for Patients With Advanced Non–Small Cell Lung Cancer
07/12/2023

Featuring Thomas Stricker, MD

Featuring Thomas Stricker, MD
Thomas Stricker, MD, PhD, speaks with the Journal of Clinical Pathways about his research on the clinical impact of the timing of first line targeted therapy in aNSCLC patients with actionable driver oncogenes.
Thomas Stricker, MD, PhD, speaks with the Journal of Clinical Pathways about his research on the clinical impact of the timing of first line targeted therapy in aNSCLC patients with actionable driver oncogenes.
Thomas Stricker, MD, PhD, speaks...
07/12/2023
Journal of Clinical Pathways
ASCO Updates Systemic Therapy Guideline for NSCLC With Driver Alterations
ASCO Updates Systemic Therapy Guideline for NSCLC With Driver Alterations
03/09/2021

Janelle Bradley

Janelle Bradley
The American Society of Clinical Oncology released an update to its guideline on systemic therapy for patients with stage IV non-small cell lung cancer with driver alterations.
The American Society of Clinical Oncology released an update to its guideline on systemic therapy for patients with stage IV non-small cell lung cancer with driver alterations.
The American Society of Clinical...
03/09/2021
Journal of Clinical Pathways
News
Higher Out-of-Pocket Costs Associated With Decreased TKI Adherence in NSCLC
02/15/2021
02/15/2021
Journal of Clinical Pathways
News
Timely Specialty Palliative Care for NSCLC Associated With Cost-Savings
12/17/2020
12/17/2020
Journal of Clinical Pathways
News
Real-World Outcomes of Companion Diagnostic Testing in Advanced NSCLC
07/09/2020
A new study published in The Oncologist (online July 6, 2020; doi:10.1634/theoncologist.2019-0864) demonstrated the clinical utility of companion diagnostic testing as a first step in treating non-squamous advanced...
A new study published in The Oncologist (online July 6, 2020; doi:10.1634/theoncologist.2019-0864) demonstrated the clinical utility of companion diagnostic testing as a first step in treating non-squamous advanced...
A new...
07/09/2020
Journal of Clinical Pathways
News
NCCN Biomarker Guideline Adherence Linked With Decreased Mortality in NSCLC
06/16/2020
Adherence to the National Comprehensive Cancer Network (NCCN) guideline for biomarker testing for non-squamous advanced non-small cell lung cancer (NSCLC) is associated with decreased risk of mortality, according to a recent...
Adherence to the National Comprehensive Cancer Network (NCCN) guideline for biomarker testing for non-squamous advanced non-small cell lung cancer (NSCLC) is associated with decreased risk of mortality, according to a recent...
Adherence to the National...
06/16/2020
Journal of Clinical Pathways
News
Real-World Costs of Adverse Events After First-Line Treatment of Metastatic NSCLC
06/09/2020
Real-world patients with metastatic non-small cell lung cancer (NSCLC) who receive first-line immunotherapy are less likely to incur adverse event-related costs than those treated with first-line cytotoxic...
Real-world patients with metastatic non-small cell lung cancer (NSCLC) who receive first-line immunotherapy are less likely to incur adverse event-related costs than those treated with first-line cytotoxic...
...
06/09/2020
Journal of Clinical Pathways
News
Clinical Pathways Reduce Cost, Increase Clinical Trial Entry for Patients With NSCLC
05/28/2020
A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-31, 2020) demonstrated how standardized evidence-based clinical pathways can be used successfully across a large number of...
A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-31, 2020) demonstrated how standardized evidence-based clinical pathways can be used successfully across a large number of...
A...
05/28/2020
Journal of Clinical Pathways
Research Reports
Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non-Small Cell Lung Cancer Treatment Setting
02/15/2018
Casey Mason
Peter G Ellis, MD
Kathy Lokay
Amanda Barry, MPH
Natalie Dickson, MD
Ray Page, DO, PhD
Blase Polite, MD
Ravi Salgia, MD, PhD
Michael Savin, MD
Corey Shamah, MD
Mark A Socinski, MD
Abstract: Despite clear clinical benefit and guideline recommendations for predictive biomarker testing and subsequent first-line targeted therapy treatment in patients with non–small cell lung cancer (NSCLC), there...
Abstract: Despite clear clinical benefit and guideline recommendations for predictive biomarker testing and subsequent first-line targeted therapy treatment in patients with non–small cell lung cancer (NSCLC), there...
...
02/15/2018
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

May 28 ⁠–⁠ May 31
May 30 ⁠–⁠ June 2
May 30 ⁠–⁠ June 1
WoundCon
June 7
June 8 ⁠–⁠ June 9
Psych Congress Regionals
June 20 ⁠–⁠ June 21
June 21 ⁠–⁠ June 22
July 3 ⁠–⁠ July 6
Psych Congress Regionals
July 18 ⁠–⁠ July 19
July 19 ⁠–⁠ July 20
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use